About DaVita HealthCare Partners (NYSE:DVA)
DaVita Inc., formerly DaVita HealthCare Partners Inc., operates two divisions: DaVita Kidney Care (Kidney Care) and DaVita Medical Group (DMG). The Kidney Care division consists of its the United States dialysis and related lab services, its ancillary services and strategic initiatives, including its international operations, and its corporate administrative support. Its DMG division is a patient- and physician-focused integrated healthcare delivery and management company that provides medical services to members through capitation contracts. Its segments include U.S. dialysis and related lab services, DMG, and Other-Ancillary services and strategic initiatives. Its U.S. dialysis and related lab services line of business provide kidney dialysis services in the United States for patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD). As of December 31, 2016, it had operated or provided administrative services to 154 outpatient dialysis centers.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Healthcare Facilities & Services
- Sub-Industry: Health Care Services
- Symbol: NYSE:DVA
- CUSIP: 23918K10
- Web: www.davita.com
Capitalization:- Market Cap: $10.88 billion
- Outstanding Shares: 191,199,000
Average Prices:- 50 Day Moving Avg: $58.31
- 200 Day Moving Avg: $62.84
- 52 Week Range: $53.58 - $70.16
P/E:- Trailing P/E Ratio: 8.67
- Foreward P/E Ratio: 15.02
- P/E Growth: 1.22
Sales & Book Value:- Annual Revenue: $15.01 billion
- Price / Sales: 0.73
- Book Value: $26.59 per share
- Price / Book: 2.14
Profitability:- EBITDA: $2.45 billion
- Net Margins: 8.68%
- Return on Equity: 14.02%
- Return on Assets: 3.78%
Debt:- Debt-to-Equity Ratio: 1.69%
- Current Ratio: 1.45%
- Quick Ratio: 1.38%
Misc:- Average Volume: 1.80 million shs.
- Beta: 0.9
- Short Ratio: 4.52
Frequently Asked Questions for DaVita HealthCare Partners (NYSE:DVA)
What is DaVita HealthCare Partners' stock symbol?
DaVita HealthCare Partners trades on the New York Stock Exchange (NYSE) under the ticker symbol "DVA."
How will DaVita HealthCare Partners' stock buyback program work?
DaVita HealthCare Partners declared that its board has authorized a share repurchase program on Wednesday, October 11th 2017, which allows the company to buyback $1,500,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization allows the company to repurchase shares of its stock through open market purchases. Shares buyback programs are generally a sign that the company's management believes its shares are undervalued.
How were DaVita HealthCare Partners' earnings last quarter?
DaVita HealthCare Partners Inc. (NYSE:DVA) posted its quarterly earnings results on Tuesday, August, 1st. The company reported $0.92 earnings per share for the quarter, beating the Zacks' consensus estimate of $0.90 by $0.02. The company earned $3.88 billion during the quarter, compared to analysts' expectations of $3.82 billion. DaVita HealthCare Partners had a return on equity of 14.02% and a net margin of 8.68%. The company's revenue was up 4.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.01 earnings per share. View DaVita HealthCare Partners' Earnings History.
When will DaVita HealthCare Partners make its next earnings announcement?
Where is DaVita HealthCare Partners' stock going? Where will DaVita HealthCare Partners' stock price be in 2017?
9 analysts have issued twelve-month target prices for DaVita HealthCare Partners' stock. Their predictions range from $57.00 to $70.00. On average, they expect DaVita HealthCare Partners' share price to reach $65.00 in the next year. View Analyst Ratings for DaVita HealthCare Partners.
Who are some of DaVita HealthCare Partners' key competitors?
Some companies that are related to DaVita HealthCare Partners include Laboratory Corporation of America Holdings (LH), Quest Diagnostics Incorporated (DGX), Universal Health Services (UHS), NMC Health PLC (NMC), HealthSouth Corporation (HLS), Mednax (MD), Acadia Healthcare Company (ACHC), Chemed Corp. (CHE), Select Medical Holdings Corporation (SEM), Udg Healthcare PLC (UDG), LifePoint Health (LPNT), HMS Holdings Corp (HMSY), Tenet Healthcare Corporation (THC), China Cord Blood Corporation (CO), HealthStream (HSTM), Community Health Systems (CYH), Kindred Healthcare (KND) and Georgia Healthcare Group PLC (GHG).
Who are DaVita HealthCare Partners' key executives?
DaVita HealthCare Partners' management team includes the folowing people:
- Kent J. Thiry, Chairman of the Board
- James K. Hilger, Interim Chief Financial Officer, Chief Accounting Officer
- Joel Ackerman, Chief Financial Officer
- Robert Lang, President, International Business
- Javier J. Rodriguez, Chief Executive Officer - Kidney Care
- Jeanine M. Jiganti, Chief Compliance Officer
- LeAnne M. Zumwalt, Group Vice President - purchasing and government affairs
- Michael D. Staffieri, Chief Operating Officer- Kidney Care
- Kathleen Alyce Waters, Chief Legal Officer
- Peter T. Grauer, Lead Director, Independent Director
Who owns DaVita HealthCare Partners stock?
DaVita HealthCare Partners' stock is owned by a number of of retail and institutional investors. Top institutional investors include Eqis Capital Management Inc. (0.00%). Company insiders that own DaVita HealthCare Partners stock include Charles Berg, Dennis Kogod, James K Hilger, Javier Rodriguez, Jeanine Marie Jiganti, John M Nehra, Kent J Thiry, Laura Mildenberger, Leanne M Zumwalt, Michael David Staffieri, Pamela M Arway, Roger Valine and William L Roper. View Institutional Ownership Trends for DaVita HealthCare Partners.
Who bought DaVita HealthCare Partners stock? Who is buying DaVita HealthCare Partners stock?
How do I buy DaVita HealthCare Partners stock?
Shares of DaVita HealthCare Partners can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is DaVita HealthCare Partners' stock price today?
One share of DaVita HealthCare Partners stock can currently be purchased for approximately $56.93.
MarketBeat Community Rating for DaVita HealthCare Partners (NYSE DVA)MarketBeat's community ratings are surveys of what our community members think about DaVita HealthCare Partners and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for DaVita HealthCare Partners (NYSE:DVA) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 2 Sell Ratings, 6 Hold Ratings, 1 Buy Rating |
| Consensus Rating: | Hold (Score: 1.89) |
| Consensus Price Target: | $65.00 (14.18% upside) |
Consensus Price Target History for DaVita HealthCare Partners (NYSE:DVA)
Analysts' Ratings History for DaVita HealthCare Partners (NYSE:DVA)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 10/15/2017 | SunTrust Banks, Inc. | Set Price Target | Hold | $57.00 | N/A |  |
| 10/10/2017 | KeyCorp | Reiterated Rating | Hold | | N/A | |
| 10/9/2017 | J P Morgan Chase & Co | Downgrade | Neutral -> Underweight | | N/A | |
| 9/6/2017 | Royal Bank Of Canada | Reiterated Rating | Hold | $64.00 | Low | |
| 8/3/2017 | Jefferies Group LLC | Reiterated Rating | Hold | $70.00 | Medium | |
| 5/25/2017 | Goldman Sachs Group, Inc. (The) | Reiterated Rating | Sell | $62.00 | High | |
| 12/13/2016 | Robert W. Baird | Downgrade | Outperform -> Neutral | $68.00 -> $69.00 | N/A | |
| 11/21/2016 | Bank of America Corp | Reiterated Rating | Hold | $68.00 | N/A | |
| 11/1/2016 | Wells Fargo & Company | Reiterated Rating | Outperform | | N/A | |
| 9/20/2016 | Raymond James Financial, Inc. | Upgrade | Market Perform -> Outperform | $75.00 | N/A | |
| 9/6/2016 | Citigroup Inc. | Initiated Coverage | Neutral | $71.00 | N/A | |
| 4/6/2016 | Susquehanna Bancshares Inc | Boost Price Target | Neutral | $70.00 -> $78.00 | N/A | |
| 3/2/2016 | Sanford C. Bernstein | Lower Price Target | Market Perform | $74.50 -> $71.00 | N/A | |
| 2/12/2016 | William Blair | Reiterated Rating | Buy | | N/A | |
| 2/12/2016 | Piper Jaffray Companies | Reiterated Rating | Overweight | $90.00 -> $85.00 | N/A | |
(Data available from 10/16/2015 forward)
Earnings History for DaVita HealthCare Partners (NYSE:DVA)Earnings History by Quarter for DaVita HealthCare Partners (NYSE DVA)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 10/31/2017 | | $0.94 | | | | | N/A | |
| 8/1/2017 | Q2 2017 | $0.90 | $0.92 | $3.82 billion | $3.88 billion | View | Listen | |
| 5/2/2017 | Q1 2017 | $0.82 | $0.79 | $3.69 billion | $3.70 billion | View | Listen | |
| 2/16/2017 | Q4 2016 | $0.91 | $0.98 | $3.74 billion | $3.72 billion | View | Listen | |
| 11/2/2016 | Q316 | $0.94 | $0.95 | $3.72 billion | $3.73 billion | View | Listen | |
| 8/8/2016 | Q216 | $0.98 | $1.01 | $3.67 billion | $3.72 billion | View | Listen | |
| 5/4/2016 | Q116 | $0.86 | $0.92 | $3.51 billion | $3.58 billion | View | Listen | |
| 2/11/2016 | Q415 | $0.97 | $1.01 | $3.50 billion | $3.53 billion | View | Listen | |
| 11/3/2015 | Q315 | $0.97 | $1.00 | $3.46 billion | $3.53 billion | View | Listen | |
| 8/4/2015 | Q215 | $0.95 | $0.95 | $3.37 billion | $3.43 billion | View | Listen | |
| 5/4/2015 | Q115 | $0.86 | $0.86 | $3.25 billion | $3.29 billion | View | Listen | |
| 2/12/2015 | Q414 | $0.89 | $0.96 | $3.26 billion | $3.33 billion | View | Listen | |
| 11/6/2014 | Q314 | $0.91 | $0.90 | $3.19 billion | $3.25 billion | View | Listen | |
| 7/31/2014 | Q214 | $0.88 | $0.95 | $3.10 billion | $3.17 billion | View | Listen | |
| 5/1/2014 | Q1 | $0.87 | $0.85 | $3.02 billion | $3.04 billion | View | Listen | |
| 2/11/2014 | Q413 | $1.91 | $0.99 | $2.92 billion | $3.06 billion | View | Listen | |
| 11/5/2013 | Q313 | $0.96 | $0.98 | $2.93 billion | $3.00 billion | View | Listen | |
| 8/6/2013 | Q2 2013 | $1.84 | $1.84 | $2.88 billion | $2.87 billion | View | Listen | |
| 5/7/2013 | Q1 2013 | $1.80 | $1.84 | $2.78 billion | $2.83 billion | View | Listen | |
| 2/14/2013 | Q4 2012 | $1.60 | $1.85 | $2.40 billion | $2.48 billion | View | Listen | |
| 10/30/2012 | | $1.55 | $1.56 | | | View | N/A | |
| 8/1/2012 | | $1.47 | $1.49 | | | View | N/A | |
| 2/16/2012 | | $1.49 | $1.58 | | | View | N/A | |
| 11/3/2011 | | $1.46 | $1.45 | | | View | N/A | |
| 8/3/2011 | | $1.14 | $1.17 | | | View | N/A | |
| 5/2/2011 | | $0.95 | $0.96 | | | View | N/A | |
| 2/10/2011 | | $1.12 | $0.70 | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for DaVita HealthCare Partners (NYSE:DVA)2017 EPS Consensus Estimate: $3.55
2018 EPS Consensus Estimate: $3.82
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 3 | $0.77 | $0.84 | $0.81 |
| Q2 2017 | 3 | $0.90 | $0.92 | $0.91 |
| Q3 2017 | 3 | $0.90 | $0.95 | $0.93 |
| Q4 2017 | 3 | $0.90 | $0.91 | $0.91 |
| Q1 2018 | 2 | $0.85 | $0.85 | $0.85 |
| Q2 2018 | 2 | $0.97 | $0.99 | $0.98 |
| Q3 2018 | 2 | $0.99 | $1.03 | $1.01 |
| Q4 2018 | 2 | $0.97 | $0.99 | $0.98 |
| Q1 2019 | 1 | $0.92 | $0.92 | $0.92 |
| Q2 2019 | 1 | $1.08 | $1.08 | $1.08 |
(Data provided by Zacks Investment Research)
Dividend History for DaVita HealthCare Partners (NYSE:DVA)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for DaVita HealthCare Partners (NYSE:DVA)Insider Ownership Percentage: 2.00%
Institutional Ownership Percentage: 83.23%
Insider Trades by Quarter for DaVita HealthCare Partners (NYSE:DVA)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 5/15/2017 | Javier Rodriguez | CEO | Sell | 1,294 | $66.21 | $85,675.74 | |
| 5/9/2017 | Charles Berg | Director | Sell | 8,414 | $65.80 | $553,641.20 | |
| 5/4/2017 | William L Roper | Director | Sell | 12,994 | $65.89 | $856,174.66 | |
| 8/9/2016 | Michael David Staffieri | COO | Sell | 20,262 | $73.09 | $1,480,949.58 | |
| 7/11/2016 | Jeanine Marie Jiganti | Insider | Sell | 1,291 | $78.51 | $101,356.41 | |
| 7/1/2016 | Jeanine Marie Jiganti | Insider | Sell | 4,620 | $77.45 | $357,819.00 | |
| 5/25/2016 | Pamela M Arway | Director | Sell | 10,824 | $77.16 | $835,179.84 | |
| 5/23/2016 | James K Hilger | CFO | Sell | 3,416 | $76.79 | $262,314.64 | |
| 5/20/2016 | Kent J Thiry | CEO | Sell | 32,880 | $76.99 | $2,531,431.20 | |
| 5/17/2016 | Dennis Kogod | CEO | Sell | 17,700 | $77.35 | $1,369,095.00 | |
| 5/17/2016 | Leanne M Zumwalt | VP | Sell | 538 | $77.08 | $41,469.04 | |
| 5/16/2016 | James K Hilger | CFO | Sell | 3,983 | $75.59 | $301,074.97 | |
| 5/16/2016 | Javier Rodriguez | CEO | Sell | 36,466 | $75.44 | $2,750,995.04 | |
| 5/16/2016 | Michael David Staffieri | COO | Sell | 4,934 | $75.69 | $373,454.46 | |
| 5/12/2016 | Roger Valine | Director | Sell | 8,220 | $76.34 | $627,514.80 | |
| 5/10/2016 | Dennis Kogod | CEO | Sell | 40,048 | $76.25 | $3,053,660.00 | |
| 5/6/2016 | John M Nehra | Director | Sell | 16,314 | $75.56 | $1,232,685.84 | |
| 4/11/2016 | Javier Rodriguez | CEO | Sell | 89,912 | $73.51 | $6,609,431.12 | |
| 3/21/2016 | Dennis Kogod | CEO | Sell | 13,455 | $72.12 | $970,374.60 | |
| 2/29/2016 | Pamela M Arway | Director | Sell | 9,026 | $66.00 | $595,716.00 | |
| 2/23/2016 | Leanne M. Zumwalt | VP | Sell | 14,587 | $64.25 | $937,214.75 | |
| 2/16/2016 | Dennis Kogod | CEO | Sell | 33,290 | $61.99 | $2,063,647.10 | |
| 12/17/2015 | Laura Mildenberger | insider | Sell | 1,440 | $68.14 | $98,121.60 | |
| 9/22/2015 | Kim M. Rivera | insider | Sell | 40,037 | $75.48 | $3,021,992.76 | |
| 8/17/2015 | Carol Anthony Davidson | Director | Sell | 4,038 | $79.93 | $322,757.34 | |
| 6/4/2015 | Robert J Margolis | Chairman | Sell | 31,400 | $83.39 | $2,618,446.00 | |
| 5/28/2015 | Michael David Staffieri | COO | Sell | 9,050 | $84.07 | $760,833.50 | |
| 5/19/2015 | Robert J Margolis | Chairman | Sell | 15,700 | $83.22 | $1,306,554.00 | |
| 5/18/2015 | James K Hilger | CFO | Sell | 3,983 | $82.10 | $327,004.30 | |
| 5/18/2015 | Michael David Staffieri | COO | Sell | 2,047 | $82.03 | $167,915.41 | |
| 5/18/2015 | Robert J Margolis | Chairman | Sell | 15,700 | $82.24 | $1,291,168.00 | |
| 5/11/2015 | James K Hilger | CFO | Sell | 8,267 | $82.00 | $677,894.00 | |
| 5/11/2015 | Jeanine Marie Jiganti | Insider | Sell | 2,481 | $81.95 | $203,317.95 | |
| 5/11/2015 | John M Nehra | Director | Sell | 12,278 | $81.85 | $1,004,954.30 | |
| 4/21/2015 | Robert J Margolis | Chairman | Sell | 31,400 | $82.40 | $2,587,360.00 | |
| 4/7/2015 | Robert J Margolis | Chairman | Sell | 15,700 | $82.15 | $1,289,755.00 | |
| 4/6/2015 | Robert J Margolis | Chairman | Sell | 15,700 | $81.49 | $1,279,393.00 | |
| 3/27/2015 | Robert J Margolis | Chairman | Sell | 31,400 | $81.18 | $2,549,052.00 | |
| 3/12/2015 | Robert J Margolis | Chairman | Sell | 107,374 | $79.24 | $8,508,315.76 | |
| 2/27/2015 | Robert J Margolis | Chairman | Sell | 21,000 | $74.29 | $1,560,090.00 | |
| 2/19/2015 | Robert J Margolis | Chairman | Sell | 21,000 | $73.12 | $1,535,520.00 | |
| 1/30/2015 | Robert J Margolis | Chairman | Sell | 31,400 | $75.48 | $2,370,072.00 | |
| 1/23/2015 | Michael David Staffieri | COO | Sell | 21,869 | $76.05 | $1,663,137.45 | |
| 1/16/2015 | Robert J Margolis | Chairman | Sell | 31,400 | $74.92 | $2,352,488.00 | |
| 1/8/2015 | Kim M Rivera | Insider | Sell | 1,111 | $75.10 | $83,436.10 | |
| 12/30/2014 | Robert J Margolis | Chairman | Sell | 31,400 | $76.09 | $2,389,226.00 | |
| 12/29/2014 | Robert J Margolis | Chairman | Sell | 15,700 | $76.09 | $1,194,613.00 | |
| 12/19/2014 | Laura Mildenberger | Insider | Sell | 1,446 | $75.50 | $109,173.00 | |
| 12/18/2014 | Robert J Margolis | Chairman | Sell | 31,400 | $74.67 | $2,344,638.00 | |
| 12/3/2014 | Robert J Margolis | Chairman | Sell | 31,400 | $75.80 | $2,380,120.00 | |
| 12/1/2014 | Kim M Rivera | Insider | Sell | 6,503 | $76.08 | $494,748.24 | |
| 11/21/2014 | Robert J Margolis | Chairman | Sell | 31,400 | $75.08 | $2,357,512.00 | |
| 11/11/2014 | Kent J Thiry | CEO | Sell | 344,938 | $74.52 | $25,704,779.76 | |
| 11/11/2014 | Robert J Margolis | Chairman | Sell | 250,000 | $75.09 | $18,772,500.00 | |
| 11/10/2014 | Berkshire Hathaway Inc | Major Shareholder | Buy | 944,418 | $74.11 | $69,990,817.98 | |
| 11/7/2014 | R. Ted Weschler | Major Shareholder | Buy | 820,018 | $74.10 | $60,763,333.80 | |
| 11/3/2014 | Roger Valine | Director | Sell | 7,185 | $77.85 | $559,352.25 | |
| 9/16/2014 | John M Nehra | Director | Sell | 20,000 | $73.91 | $1,478,200.00 | |
| 9/8/2014 | Kim M Rivera | Insider | Sell | 1,111 | $74.25 | $82,491.75 | |
| 8/27/2014 | Leanne M Zumwalt | VP | Sell | 3,214 | $74.57 | $239,667.98 | |
| 8/11/2014 | Jeanine Marie Jiganti | Insider | Sell | 2,500 | $72.14 | $180,350.00 | |
| 6/11/2014 | Kim M Rivera | Insider | Sell | 5,929 | $71.05 | $421,255.45 | |
| 5/29/2014 | Laura Mildenberger | Insider | Sell | 5,080 | $69.99 | $355,549.20 | |
| 5/16/2014 | Dennis Kogod | COO | Sell | 18,750 | $67.30 | $1,261,875.00 | |
| 5/16/2014 | Kent Thiry | CEO | Sell | 17,600 | $67.41 | $1,186,416.00 | |
| 5/15/2014 | James Hilger | CAO | Sell | 1,666 | $67.23 | $112,005.18 | |
| 5/15/2014 | Javier Rodriguez | CEO | Sell | 7,000 | $67.50 | $472,500.00 | |
| 5/12/2014 | Dennis Kogod | COO | Sell | 32,188 | $68.06 | $2,190,715.28 | |
| 5/8/2014 | Dennis Kogod | COO | Sell | 32,213 | $67.36 | $2,169,867.68 | |
| 5/7/2014 | Michael David Staffieri | COO | Sell | 2,633 | $67.30 | $177,200.90 | |
| 4/2/2014 | Michael David Staffieri | COO | Sell | 2,867 | $69.15 | $198,253.05 | |
| 3/20/2014 | Laura Mildenberger | Insider | Sell | 3,274 | $70.04 | $229,310.96 | |
| 2/26/2014 | R. Ted Weschler | major shareholder | Buy | 1,159,858 | $66.97 | $77,675,690.26 | |
| 2/21/2014 | John Nehra | Director | Sell | 40,000 | $65.81 | $2,632,400.00 | |
| 2/18/2014 | William Roper | Director | Sell | 42,519 | $66.37 | $2,821,986.03 | |
| 12/20/2013 | Laura Mildenberger | Insider | Sell | 10,417 | $62.53 | $651,375.01 | |
| 12/17/2013 | Allen Nissenson | Insider | Sell | 2,929 | $59.83 | $175,242.07 | |
| 12/9/2013 | Berkshire Hathaway Inc | major shareholder | Buy | 1,314,170 | $57.84 | $76,011,592.80 | |
| 11/8/2013 | R. Ted Weschler | major shareholder | Buy | 3,700,294 | $55.14 | $204,034,211.16 | |
| 7/5/2013 | Berkshire Hathaway Inc | Major Shareholder | Buy | 110,309 | $114.01 | $12,576,329.09 | |
| 7/3/2013 | R. Ted Weschler | Major Shareholder | Buy | 639,200 | $114.78 | $73,367,376.00 | |
| 5/15/2013 | David T Shapiro | Insider | Sell | 8,779 | $129.80 | $1,139,514.20 | |
| 5/15/2013 | Dennis Kogod | COO | Sell | 21,130 | $129.47 | $2,735,701.10 | |
| 5/15/2013 | James K Hilger | CFO | Sell | 1,049 | $130.18 | $136,558.82 | |
| 5/15/2013 | Leanne M Zumwalt | VP | Sell | 13,209 | $129.59 | $1,711,754.31 | |
| 5/13/2013 | Kent J Thiry | CEO | Sell | 243,307 | $129.95 | $31,617,744.65 | |
| 5/13/2013 | Kim M Rivera | Insider | Sell | 1,672 | $129.70 | $216,858.40 | |
| 3/4/2013 | Berkshire Hathaway Inc | Major Shareholder | Buy | 164,947 | $119.59 | $19,726,011.73 | |
| 3/4/2013 | Roger Valine | Director | Sell | 1,390 | $120.00 | $166,800.00 | |
| 2/27/2013 | Berkshire Hathaway Inc | Major Shareholder | Buy | 211,889 | $116.56 | $24,697,781.84 | |
| 2/22/2013 | Berkshire Hathaway Inc | Major Shareholder | Buy | 224,091 | $115.88 | $25,967,665.08 | |
| 2/19/2013 | Berkshire Hathaway Inc | Major Shareholder | Buy | 323,070 | $116.73 | $37,711,961.10 | |
| 2/5/2013 | Berkshire Hathaway Inc | Major Shareholder | Buy | 32,376 | $115.17 | $3,728,743.92 | |
| 2/4/2013 | Roger Valine | Director | Sell | 1,389 | $116.13 | $161,304.57 | |
| 1/16/2013 | Berkshire Hathaway Inc | Major Shareholder | Buy | 42,400 | $111.33 | $4,720,392.00 | |
| 1/15/2013 | Berkshire Hathaway Inc | Major Shareholder | Buy | 179,300 | $109.67 | $19,663,831.00 | |
| 1/10/2013 | Berkshire Hathaway Inc | Major Shareholder | Buy | 187,898 | $109.54 | $20,582,346.92 | |
| 12/24/2012 | Dennis Kogod | COO | Sell | 12,736 | $111.00 | $1,413,696.00 | |
| 12/21/2012 | James K Hilger | CFO | Sell | 2,073 | $112.20 | $232,590.60 | |
| 12/6/2012 | Berkshire Hathaway Inc | Major Shareholder | Buy | 635,633 | $106.20 | $67,504,224.60 | |
| 11/29/2012 | Berkshire Hathaway Inc | Major Shareholder | Buy | 679,249 | $108.20 | $73,494,741.80 | |
| 11/26/2012 | Berkshire Hathaway Inc | Major Shareholder | Buy | 412,050 | $110.38 | $45,482,079.00 | |
| 11/16/2012 | Berkshire Hathaway Inc | Major Shareholder | Buy | 132,958 | $112.45 | $14,951,127.10 | |
| 11/12/2012 | Berkshire Hathaway Inc | Major Shareholder | Buy | 548,823 | $112.15 | $61,550,499.45 | |
| 11/7/2012 | Berkshire Hathaway Inc | Major Shareholder | Buy | 139,491 | $112.03 | $15,627,176.73 | |
| 11/2/2012 | Berkshire Hathaway Inc | Major Shareholder | Buy | 254,750 | $112.20 | $28,582,950.00 | |
| 10/26/2012 | Berkshire Hathaway Inc | Major Shareholder | Buy | 257,941 | $111.14 | $28,667,562.74 | |
| 10/17/2012 | Berkshire Hathaway Inc | Major Shareholder | Buy | 63,928 | $109.56 | $7,003,951.68 | |
| 10/12/2012 | Berkshire Hathaway Inc | Major Shareholder | Buy | 217,597 | $109.76 | $23,883,446.72 | |
| 10/9/2012 | Berkshire Hathaway Inc | Major Shareholder | Buy | 67,946 | $107.71 | $7,318,463.66 | |
| 9/28/2012 | Berkshire Hathaway Inc | Major Shareholder | Buy | 282,403 | $102.03 | $28,813,578.09 | |
| 8/8/2012 | Kent J Thiry | Chairman | Sell | 320,877 | $96.88 | $31,086,563.76 | |
| 8/7/2012 | William L Roper | Director | Sell | 23,019 | $95.95 | $2,208,673.05 | |
(Data available from 1/1/2013 forward)
Headline Trends for DaVita HealthCare Partners (NYSE:DVA)
Latest Headlines for DaVita HealthCare Partners (NYSE:DVA)
| Source: |
|
| Date | Headline |
|---|
 | DaVita Provides Additional Information Regarding Patients Receiving Charitable Premium Assistance
finance.yahoo.com - October 16 at 6:46 PM |
| DaVita Inc. Schedules 3rd Quarter 2017 Investor Conference Call
finance.yahoo.com - October 16 at 6:46 PM |
| DaVita estimates charitable assistance loss would total up to $250M
finance.yahoo.com - October 16 at 6:46 PM |
| The Hot Stock: DaVita Surges
finance.yahoo.com - October 16 at 6:46 PM |
 | Head to Head Analysis: DaVita HealthCare Partners (DVA) and Its Peers
www.americanbankingnews.com - October 15 at 4:28 AM |
| ETFs with exposure to DaVita, Inc. : October 13, 2017
finance.yahoo.com - October 13 at 6:37 PM |
| FY2019 EPS Estimates for DaVita HealthCare Partners Inc. Decreased by Analyst (DVA)
www.americanbankingnews.com - October 13 at 3:26 PM |
| Reviewing DaVita HealthCare Partners (DVA) and Select Medical Holdings Corporation (SEM)
www.americanbankingnews.com - October 12 at 8:34 PM |
 | Pro-Trader Daily: Corporate News Blog - DaVita Divulges Information Regarding Charitable Premium Assistance
www.finanznachrichten.de - October 12 at 6:52 PM |
| DaVita Announced as New Partner for The Denver Post Season to Share
finance.yahoo.com - October 12 at 6:52 PM |
| Corporate News Blog - DaVita Divulges Information Regarding Charitable Premium Assistance
finance.yahoo.com - October 12 at 6:52 PM |
| KeyCorp Comments on DaVita HealthCare Partners Inc.'s FY2018 Earnings (DVA)
www.americanbankingnews.com - October 12 at 1:54 PM |
| Zacks Investment Research Lowers DaVita HealthCare Partners Inc. (DVA) to Sell
www.americanbankingnews.com - October 11 at 3:22 PM |
| DaVita HealthCare Partners (DVA) to Buyback $1.50 billion in Shares
www.americanbankingnews.com - October 11 at 11:08 AM |
| Comparing DaVita HealthCare Partners (DVA) & Air Methods Corp (AIRM)
www.americanbankingnews.com - October 11 at 2:10 AM |
| Rite Aid, Walgreens Once Again Dip into Tuesday’s 52-Week Low Club
finance.yahoo.com - October 10 at 8:49 PM |
 | DaVita Banks on Acquisitions, Escalating Expenses a Concern - Nasdaq
www.nasdaq.com - October 10 at 3:49 PM |
| DaVita Provides Disclosures Regarding Charitable Premium Assistance
finance.yahoo.com - October 10 at 3:48 PM |
| DaVita VillageHealth Receives Disease Management Recertification
finance.yahoo.com - October 10 at 3:48 PM |
| Downgrade, stock slide prompts DaVita kidney-fund response
finance.yahoo.com - October 10 at 3:48 PM |
| More Than 18,000 Technicians Contribute to Life-Saving Care
finance.yahoo.com - October 9 at 6:25 PM |
| JP Morgan: Hasta DaVita!
finance.yahoo.com - October 9 at 6:25 PM |
| Why DaVita Inc. Sank Lower Today
finance.yahoo.com - October 9 at 6:25 PM |
| Why Viacom, DaVita, and K2M Group Holdings Slumped Today
finance.yahoo.com - October 9 at 6:24 PM |
| The Biggest Loser: DaVita Tumbles 9.9%
finance.yahoo.com - October 9 at 6:24 PM |
| DaVita: Buffett's Next Acquisition?
finance.yahoo.com - October 3 at 9:33 AM |
| Should Value Investors Consider DaVita Inc. (DVA) Stock?
finance.yahoo.com - October 3 at 9:33 AM |
| DaVita, Inc. :DVA-US: Earnings Analysis: Q2, 2017 By the Numbers : September 29, 2017
finance.yahoo.com - October 3 at 9:33 AM |
| ETFs with exposure to DaVita, Inc. : October 2, 2017
finance.yahoo.com - October 3 at 9:33 AM |
| More Than 600 Cyclists to Ride through Washington State in 11th Annual Tour DaVita
finance.yahoo.com - October 3 at 9:33 AM |
| Financial Comparison: Streamline Health Solutions (STRM) versus DaVita HealthCare Partners (DVA)
www.americanbankingnews.com - October 1 at 6:24 AM |
| Critical Comparison: HealthSouth Corporation (HLS) vs. DaVita HealthCare Partners (DVA)
www.americanbankingnews.com - September 30 at 2:24 PM |
| Financial Comparison: DaVita HealthCare Partners (DVA) & Its Peers
www.americanbankingnews.com - September 29 at 6:24 PM |
| Nobilis Health Corp (HLTH) vs. DaVita HealthCare Partners (DVA) Head to Head Analysis
www.americanbankingnews.com - September 26 at 2:32 PM |
| Traders Purchase Large Volume of Put Options on DaVita HealthCare Partners (DVA)
www.americanbankingnews.com - September 25 at 8:52 AM |
| DaVita HealthCare Partners Inc. (DVA) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - September 24 at 2:48 PM |
| The Biggest Loser: DaVita Dives
finance.yahoo.com - September 22 at 5:07 PM |
| DaVita, Inc. breached its 50 day moving average in a Bullish Manner : DVA-US : September 19, 2017
finance.yahoo.com - September 19 at 6:03 PM |
| November 17th Options Now Available For DaVita (DVA)
www.nasdaq.com - September 18 at 5:53 PM |
| DaVita HealthCare Partners Inc. to Post Q1 2019 Earnings of $0.92 Per Share, SunTrust Banks Forecasts (DVA)
www.americanbankingnews.com - September 18 at 8:00 AM |
| DaVita's (DVA) Green Initiatives Win a Coveted Golden Reward
finance.yahoo.com - September 14 at 3:38 PM |
| $3.83 Billion in Sales Expected for DaVita HealthCare Partners Inc. (DVA) This Quarter
www.americanbankingnews.com - September 14 at 1:54 AM |
| DaVita HealthCare (DVA) Down 9.1% Since Earnings Report: Can It Rebound? - Nasdaq
www.nasdaq.com - September 11 at 6:38 PM |
| DaVita HealthCare (DVA) Down 9.1% Since Earnings Report: Can It Rebound?
finance.yahoo.com - September 11 at 6:38 PM |
| DaVita Kidney Care Celebrates its 18,000 Nephrology Nurses
finance.yahoo.com - September 11 at 6:38 PM |
| DaVita HealthCare Partners Inc. (DVA) Earns Hold Rating from Royal Bank Of Canada
www.americanbankingnews.com - September 6 at 9:40 PM |
| DaVita Inc. to Participate in RW Baird 2017 Global Healthcare Conference
finance.yahoo.com - September 1 at 6:24 PM |
| DaVita HealthCare Partners Inc. (DVA) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - August 30 at 5:06 PM |
| DaVita Announces Veterans Hiring Initiative
finance.yahoo.com - August 24 at 7:00 PM |
| DaVita HealthCare Partners (DVA) & Community Health Systems (CYH) Head-To-Head Survey
www.americanbankingnews.com - August 20 at 2:28 PM |
DaVita HealthCare Partners (DVA) Chart for Monday, October, 16, 2017
